Berlin - Delayed Quote EUR
Novavax Inc (NVV1.BE)
5.37
-0.13
(-2.45%)
As of 8:08:25 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
682.16M
682.16M
556.38M
1.60B
197.58M
Cost of Revenue
202.74M
202.74M
343.77M
902.64M
0.00
Gross Profit
479.42M
479.42M
212.61M
696.31M
197.58M
Operating Expense
728.35M
728.35M
779.12M
1.34B
1.88B
Operating Income
-248.93M
-248.93M
-566.51M
-644.74M
-1.69B
Net Non Operating Interest Income Expense
-20.07M
-20.07M
-14.42M
-19.88M
-21.13M
Other Income Expense
92.39M
92.39M
37.90M
10.97M
-6.83M
Pretax Income
-176.62M
-176.62M
-543.03M
-653.65M
-1.71B
Tax Provision
10.88M
10.88M
2.03M
4.29M
29.21M
Net Income Common Stockholders
-187.50M
-187.50M
-545.06M
-657.94M
-1.74B
Diluted NI Available to Com Stockholders
-187.50M
-187.50M
-545.06M
-657.94M
-1.74B
Basic EPS
-1.23
-1.23
-5.41
-8.42
-23.44
Diluted EPS
-1.23
-1.23
-5.41
-8.42
-23.44
Basic Average Shares
152.19M
152.19M
100.77M
78.18M
74.40M
Diluted Average Shares
152.19M
152.19M
100.77M
78.18M
74.40M
Total Operating Income as Reported
-248.93M
-248.93M
-566.51M
-644.74M
-1.69B
Total Expenses
931.09M
931.09M
1.12B
2.24B
1.88B
Net Income from Continuing & Discontinued Operation
-187.50M
-187.50M
-545.06M
-657.94M
-1.74B
Normalized Income
-228.54M
-228.54M
-545.06M
-657.94M
-1.74B
Interest Expense
20.07M
20.07M
14.42M
19.88M
21.13M
Net Interest Income
-20.07M
-20.07M
-14.42M
-19.88M
-21.13M
EBIT
-156.54M
-156.54M
-528.62M
-633.77M
-1.69B
EBITDA
-108.04M
-108.04M
-487.39M
-604.71M
-1.68B
Reconciled Cost of Revenue
202.74M
202.74M
343.77M
902.64M
0.00
Reconciled Depreciation
48.50M
48.50M
41.23M
29.05M
12.66M
Net Income from Continuing Operation Net Minority Interest
-187.50M
-187.50M
-545.06M
-657.94M
-1.74B
Total Unusual Items Excluding Goodwill
51.95M
51.95M
0.00
0.00
1.36M
Total Unusual Items
51.95M
51.95M
0.00
0.00
1.36M
Normalized EBITDA
-159.99M
-159.99M
-487.39M
-604.71M
-1.68B
Tax Rate for Calcs
0.21
0.21
0.21
0.21
0.27
Tax Effect of Unusual Items
10.91M
10.91M
0.00
0.00
0.00
12/31/2021 - 12/8/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
22UA.BE BioNTech SE
83.55
0.00%
BNTX.VI BioNTech SE
87.85
-2.01%
22UA.MU BioNTech SE
85.30
-2.23%
0QF.DE Moderna, Inc.
23.63
-3.77%
22UA.DU BioNTech SE
85.00
+1.07%
LYEL Lyell Immunopharma, Inc.
0.4157
-4.33%
FHTX Foghorn Therapeutics Inc.
3.9800
+2.58%
22UA.DE BioNTech SE
87.95
-1.95%
IPA ImmunoPrecise Antibodies Ltd.
0.4765
+3.90%
ENSC Ensysce Biosciences, Inc.
2.1700
-12.15%